Showing results (1231-1240 of 1,708) with videos related to
Sort By:
Pageof 171
JAMA Neurology|November 10, 2015
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen ActivatorYing Xian, Jerome J Federspiel, Maria Grau-Sepulveda, et al.Atherosclerosis|March 27, 2018
External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarctionBrent A Williams, Kevin M Chagin, Lori D Bash, et al.American Heart Journal|July 6, 2010
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)Sergio Leonardi, Sunil V Rao, Robert A Harrington, et al.European Journal of Preventive Cardiology|August 7, 2013
Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosisJacob A Udell, Ph Gabriel Steg, Benjamin M Scirica, et al.JACC. Cardiovascular Imaging|March 10, 2026
Epicardial Adipose Tissue, Coronary Plaque Progression, and Major Adverse Cardiovascular Events: A Multicenter StudyAnnalisa Filtz, Daniel Lorenzatti, Andrea Scotti, et al.Journal of the American Heart Association|November 6, 2016
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary SyndromesJan H Cornel, E Magnus Ohman, Benjamin Neely, et al.Clinical Cardiology|April 4, 2019
Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI RegistryHanumantha R Jogu, Sameer Arora, Muthiah Vaduganathan, et al.Journal of the American Heart Association|May 3, 2024
Moderate Aortic Valve Stenosis Is Associated With Increased Mortality Rate and Lifetime Loss: Systematic Review and Meta-Analysis of Reconstructed Time-to-Event Data of 409 680 PatientsXander Jacquemyn, Jordan B Strom, Geoff Strange, et al.American Journal of Preventive Cardiology|July 3, 2026
Associations of VICTORION-1 PREVENT eligibility with subclinical cardiovascular and inflammatory damage in a European population-based cohortNelson Wang, Deepak L Bhatt, Constance Xhaard, et al.Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.Pageof 171